InFlectis BioScience is engaged in selectively targeting Integrated Stress Response through PPP1R15A target (also named GADD34) with small molecule inhibitors to effectively treat patients with serious and life-threatening diseases.

We have identified first-in-class small-molecule drugs that selectively target PPP1R15A the stress induced regulatory subunit of the phosphatase PP1C – an emerging target with a broad potential to treat several diseases with unmet needs.